Selective Androgen Receptor Modulators (SARMs) in the World of Sports

Onur Oral¹, George Nomikos², Nikitas Nomikos³4,*

¹Department of Health Sciences and Sports, Ege University Faculty of Sport Sciences, Izmir, Turkey
²Department of Orthopaedic Surgery, Chios Hospital, Chios, Greece
³School of Physical Education & Sport Science, National & Kapodistrian University of Athens
⁴Medical School, National & Kapodistrian University of Athens, Greece

*Corresponding author: niknomikos@med.uoa.gr

Received July 29, 2020; Revised August 31, 2020; Accepted September 09, 2020

Abstract Background: The study aims to investigate the effects of selective androgen receptor modulators (SARMs) among athletes and examine the possible beneficial results and risks of these substances for the athletes' health and performance and human health in general. Nowadays, SARMs have become a focus of interest in the world of sports and medicine. Because of their anabolic action, SARMs are considered quite promising for treating several disorders including breast cancer, osteoporosis, DMD (Duchenne Muscular Dystrophy), some type of tumors, etc. As for the athletic community, SARMs are used as doping for muscle mass increasing and strengthening and pose as an alternative to other steroid-based doping with their minimum side effects. SARMs are innovative substances for athletic performance and human health. Further study on SARMs is required in order to understand the long-term effects on human health and athletic performance.

Keywords: SARMs, anabolic action, testosterone, doping

Cite This Article: Onur Oral, George Nomikos, and Nikitas Nomikos, “Selective Androgen Receptor Modulators (SARMs) in the World of Sports.” American Journal of Medical Sciences and Medicine, vol. 8, no. 4 (2020): 153-156. doi: 10.12691/ajmsm-8-4-3.

1. Introduction

Regarding their anabolic action and therapeutic potential, selective androgen receptor modulators, SARMs, have been a focus of attention in the world of medicine [1,2,3]. The discovery of SARMs dates back to the late 1990s. These compounds affect the androgen receptors in muscles and bones. SARMs are assumed to have a curative influence on certain disorders and diseases such as tumors, Alzheimer’s Disease, breast cancer, osteoporosis, etc. Several studies have been conducted on selective androgen receptor modulators and their effect on the human body. However, SARMs' true potential and risks are not fully understood nor studied [4,5,6,7,8,9].

One reason the discovery of SARMs has considered such an important development is that they have the potential to pose as an alternative cure instead of testosterone. Testosterone is used commonly in the medical area for its therapeutic effects, yet this treatment offers many possible side effects. Most of these side effects are caused by steroids. SARMs on the other hand, are free of steroid-based side effects [10,11].

World Anti-Doping Agency (WADA) has banned certain anabolic compounds that help athletes to improve their performance. Even though the use of SARMs is quite promising in terms of their therapeutic effects, these molecules are also used as doping by athletes. Therefore, the World Anti-Doping Agency has prohibited SARMs in 2008. There is an ongoing debate on SARMs about whether they are safe for the athlete's health. Even though there is no conclusion on the issue, these substances can be obtained easily [12,13].

1.1. SARMs and Testosterone

SARMs is not an innovation only in the world of medicine but also in the world of sports as well. Doping use is quite common in the competitive field. Yet, doping especially those with steroids that are used for a long period bring along possible side effects. SARMs, on the other side, are free of some of the steroid-based health issues such as sexual dysfunction, hypogonadism, testicular atrophy, arrhythmia, hypertension, certain heart-related disorders, mental and behavior disorders, etc. [14,15,16]. In fact, according to some researches, SARM RAD140 is argued to have a beneficial influence on the nervous system [17].

And also, a recent study indicates that hormone treatment with testosterone may cause problems with the prostate and cardiovascular system [18].

1.2. Therapeutic Promise of SARMs

1.2.1. Osteoporosis

As recent studies on animals indicate SARMs are
Selective Androgen Receptor Modulators have become a focus of interest in the world of sports and medicine. Because of their anabolic action, SARMs are considered quite promising for treating several disorders including breast cancer, osteoporosis, DMD, tumors, etc. As for the athletic community, SARMs are used as doping for muscle mass increasing and strengthening. SARMs, which are banned by WADA, pose as an alternative to other steroid-based doping with their minimum side effects. SARMs are innovative substances for

2. Discussion

It was conducted on mice to analyze how androgen receptor agonists influence bone mass. SARMs were one of the compounds that were used in animal subjects and it was concluded that SARMs restrain the loss of bone mass and increase the mineral amount in bones in animal trials [36].

SARMs are assumed to be promising in the treatment of DMD. One research used GLPG0492 type of SARM on a trial with mice that have DMD mutation. SARM was used as a treatment method. The researchers observed an increase in muscle mass and improvement in muscular function. Even though this study does not suggest SARM as a certain cure for DMD, it offers a therapy method that may be improved and further used [37].

One study investigated the relationship between bones and SARM. The type of SARM used in the study is LGD-4033. The research was conducted with a group of young males in 21 days. The subjects received SARM or a placebo. Those who were treated with SARM had more lean body mass at the end of the study. Besides, their leg strength was also observed to have increased [38].

In one study, SARM MK-773 was used. The study consisted of 170 females over age 65. While half the subject group received MK-773, the others received a placebo instead. At the end of the research, females who received SARM MK-773 have more lean body mass compared to before [39].

In several studies that were conducted on mice, different types of SARMs such as S-23, S-24, S-27 were found out to positively affect sexual motivation. Also, the myometrial thickness was observed to have increased with the use of different types of SARMs [33].

In their research, Nejishima et al. questioned how Benign Prostatic Hyperplasia can be cured using SARM S-40542 or flutamide. Weight of prostate lowered as a result of both of the substances. However, Levator ani muscle, FSH, LH, etc. were less affected by SARM. The study suggests that SARMs, with their ability to avoid side effects, may be quite promising for the therapy of BPH [40].

It was investigated the relationship between SARMs and Alzheimer’ disease; SARM NEP28 was used in the research. According to the results, neprilysin activity scaled up, androgenic effects were observed to have decreased [34].

3. Conclusion

Selective Androgen Receptor Modulators have become a focus of interest in the world of sports and medicine. Because of their anabolic action, SARMs are considered quite promising for treating several disorders including breast cancer, osteoporosis, DMD, tumors, etc. As for the athletic community, SARMs are used as doping for muscle mass increasing and strengthening. SARMs, which are banned by WADA, pose as an alternative to other steroid-based doping with their minimum side effects. SARMs are innovative substances for
athletic performance and human health. However, even though many studies indicate promising therapeutic results, SARMs are not proved to be safe either. Further study on SARMs is required to understand the long-term effects on human health and athletic performance.

Conflict of Interest
No declared.

References
[1] Clark R.V., Walker A.C., Andrews S., Turnbull P., Wald J.A., Magee M.H., Safety, pharmacokinetics, and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women, Br J Clin Pharmacol, 2017, 83(10): 2179-2194.
[2] Saitoh M., Ebner N., von Haehling S., Anker S.D., Springer J., Therapeutic considerations of sarcopenia in heart failure patients, Expert Rev Cardiovasc Ther., 2018, 16(2): 133-142.
[3] Srinath R., Dobs A., Enobosarm (GTx-024, S-22): a potential treatment for cachexia, Future Oncol., 2014, 10(2): 187-194.
[4] Coss C.C., Jones A., Hancock M.L., Steiner M.S., Dalton J.T., Selective androgen receptor modulators for the treatment of late-onset male hypogonadism, Asian J Androl., 2014, 16: 256-261.
[5] Megumi M., Katsuji A., Takahito H., Masuo Y., Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models, Oncol Lett., 2017, 14: 1006-8071.
[6] Narayanan R., Ahn S., Cheney M.D., Yeperu M., Miller D.D., Steiner M.S., Dalton J.T., Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial: mesenchymal stem cell signaling, Plos One, 2014, 9(7): 100-202. 27.
[7] Narayanan R., Coss C.C., Dalton J.T., Development of selective androgen receptor modulators (SARMs), Mol Cell Endocrinol., 2108, 465: 134-142.
[8] Narayanan R., Dalton J.T., Androgen receptor: A complex androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product, Drug Test Anal, 2009, 1, pp. 387-392.
[9] Miosos J., Toso-Vesca A., Varo C.E., et al., Selective Androgen Receptor Modulators (SARMs) In The Context Of Doping, Farmacia, 2018, 66 (5): 758-762.
[10] Krishnan V., Patel N.J., Mackrell J.G., et al., Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients. Andrology, 2018, 6(3): 455-464.
[11] Pantea-Stoian A., Piturcu S.M., Hainarotea R., Testosterone therapy, new opportunities in diabetes mellitus, Farmacia, 2018, 66(1): 1-7.
[12] World Anti-Doping Agency. The 2018 Prohibited List, 2018, www.wada-ama.org.
[13] World Anti-Doping Agency. World Anti-Doping Code, 2018. www.wada-ama.org.
[14] Rahnuma C.D., Lipshultz L.I., Crosnoe L.E., et al., Anabolic steroid-induced hypogonadism: diagnosis and treatment, Fertil Steril., 2014, 101(5): 1271-1279.
[15] Wagels L., Votinov M., Kellermann T., et al., Exogenous Testosterone Enhances the Reactivity to Social Provocation in Males, Front Behav Neurosci., 2018, 12: 1-11.
[16] Goldmann A., Basaria S., Adverse health effects of androgen use, Moll Cell Endocrinol., 2018; 15: 464; 46-55.
[17] Jayaraman A., Christensen A., Moser V.A., et al., Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats, Endocrinol., 2014, 155: 1398-1406.
[18] Chen J., Kim J., Dalton J.T., Discovery and therapeutic promise of selective androgen receptor modulators, Mol Interv., 2005, 5(3): 173-188.
[19] Gao W., Reiser P.J., Coss C.C., et al., Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats, Endocrinology., 2005, 146: 4887-4897.
[20] Hanada K., Furuya K., Yamamoto N., et al., Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis, Biol Pharm Bull., 2013, 26: 1563-1569.
[21] Mohler M.L., Nair V.A., Hwang D.J., et al., Nonsteroidal Tissue Selective Androgen Receptor Modulators: A Promising Class of Clinical Candidates, Expert Opinion in Therapeutic Patents., 2005, 15(11): 1565-1585.
[22] Kearbey J.D., Gao W., Narayanan R., et al., Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats, Pharm Res., 2007, 24: 328-335.
[23] Carmeli E., Coleman R., Reznick A.Z., The biochemistry of aging muscle, Exp Gerontol., 2002, 37: 477-489.
[24] Bosy-Westphal A., Eichhorn C., Kutzner D., et al., The age-related decline in resting energy expenditure in humans is due to the loss of fat-free mass and to alterations in its metabolically active components, J Nutr., 2003, 133: 2356-2362.
[25] Dobs A.S., Bocca R.V., Croct C.C., et al., Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial, Lancet Oncol., 2013, 14:335-345. Eur J Pharmacol, 720, pp. 107-114.
[26] Dalton J.T., Barrette K.G., Bohl C.E., et al., The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial, J Cachexia Sarcopenia Muscle., 2011, 2: 153-161.
[27] Rahimov F., Kunkel L.M., The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy, J Cell Biol., 2013, 201: 499-510.
[28] Frankel K.A., Roiser R.J., The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum Pathol., 1976, 7:375-386.
[29] Poltano L., Nigo V., Nigo G., et al., Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies, JAMA., 1996, 275: 1335-1338. Prostate, 72, pp. 1580-1587.
[30] Simon J.A., Goldstein L., Kim N.N., et al., The role of androgens in the treatment of genitourinary syndrome of menopause (GSM), International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Menopause, 2018, 25 pp. 837-847.
[31] Vignozzi L., Corona G., Petrone L., et al., Testosterone and sexual activity, J Endocrinollnvest, 2005, 28 pp. 39-44.
[32] Solomon Z.J., Mirabal J.R., Mazar D.J., et al., Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications, Sex Med Rev, 2018, 71: 84-94.
[33] Jones A., Hwang D.J., Duke C.B., et al., Nonsteroidal selective androgen receptor modulators enhance female sexual motivation, 2010.
[34] Akita K., Harada K., Ichihara J., et al., A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate, 2013.
[35] Thevis M., Detection of the arylpropionamide-derived selective androgen receptor modulator (SARM) S-4 (Andarine) in a black-market product, Drug Test Anal, 2009, 1, pp. 387-392.
[36] Mason R.A., Morris H.A., Effects of dihydrotestosterone on bone biochemical markers in sham and oophorectomized rats, J Bone Miner Res., 1997, 12: 1431-1437.
[37] Cozzoli A., Capogrosso R.F., Scelidorio V.T., GLPG0492, a selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy, Pharmacol Res., 2013, 72: 9-24.
[38] Basaria S., Collins L., Dillon E.L., et al., The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men, J Gerontol A Biol Sci Med Sci., 2013, 68(1): 87-95.
[39] Papanicolaou D.A., Ather S.N., Zhu H., et al., A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia, J Nutr Health Aging, 2013, 17(6): 533-43.
[40] Nejishima H., Yamamoto N., Suzuki M., et al., Anti-androgenic effects of S-40542, a novel non-steroidal selective androgen receptor modulator (SARM) for the treatment of benign prostatic hyperplasia, 2012.